ClinicalTrials.gov record
Recruiting Phase 3 Interventional

IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

ClinicalTrials.gov ID: NCT07217301

Public ClinicalTrials.gov record NCT07217301. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 6:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label, Multi-center, Phase 3 Study Evaluating the Efficacy and Safety of IBI363 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Study identification

NCT ID
NCT07217301
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Fortvita Biologics (USA)Inc.
Industry
Enrollment
600 participants

Conditions and interventions

Interventions

  • Control Arm Drug
  • IBI363 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 25, 2025
Primary completion
Oct 31, 2028
Completion
Nov 30, 2029
Last update posted
Apr 26, 2026

2025 – 2029

United States locations

U.S. sites
7
U.S. states
4
U.S. cities
7
Facility City State ZIP Site status
St. Bernards Healthcare Jonesboro Arkansas 72401 Recruiting
Memorial Care Fountain Valley California 92708 Recruiting
Cancer and Blood Specialty Clinic Los Alamitos California 90720 Recruiting
Translation Research in Oncology- US, INC (TRIO-US) Los Angeles California 90025 Recruiting
D & H Cancer Research Center Margate Florida 33024 Recruiting
BRCR Global Plantation Florida 33322 Recruiting
The University of Texas M.D Anderson Cancer Ceneter (MDACC) Houston Texas 77030 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07217301, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 26, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07217301 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →